Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 13/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.45 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrouridine SCHEMBL587704 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| Tetrahydrouridine SCHEMBL127270 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| Tetrahydrouridine SCHEMBL171865 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| Tetrahydrouridine SCHEMBL11761038 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| Tetrahydrouridine SCHEMBL11759489 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| Tetrahydrouridine SCHEMBL14133787 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL10069547 | 0.87 | CDA (0.59) | CDAMAPT | |
| SCHEMBL12338486 | 0.87 | CDA (0.55) | CDAMAPT | |
| SCHEMBL12338454 | 0.87 | CDA (0.59) | CDAMAPT | |
| SCHEMBL10069752 | 0.87 | CDA (0.59) | CDAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4599498-A1 | ELECTROLYTES COMPRISING THIOAMIDES FOR USE IN ELECTROCHEMICAL BATTERIES | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2025-08-13 | — | — | EP | claimed |
| EP-3960182-B1 | COMPOSITIONS CONTAINING DECITABINE, 5-AZACYTIDINE AND TETRAHYDROURIDINE AND USES THEREOF | EPIDESTINY INC (US) | 2025-03-19 | — | — | EP | claimed |
| EP-4370127-A2 | A METHOD OF TREATING CANCER OR A BLOOD DISORDER | Ebrahem, Quteba (US) | 2024-05-22 | — | — | EP | claimed |
| WO-2024076361-A1 | ELECTROLYTES COMPRISING THIOAMIDES FOR USE IN ELECTROCHEMICAL BATTERIES | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2024-04-11 | — | — | WO | claimed |
| US-20240113339-A1 | ELECTROLYTES COMPRISING THIOAMIDES FOR USE IN ELECTROCHEMICAL BATTERIES | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2024-04-04 | — | — | US | claimed |
| US-20230142647-A1 | METHOD OF TREATING CANCER OR A BLOOD DISORDER | EBRAHEM QUTEBA (US) | 2023-05-11 | — | — | US | claimed |
| US-20230055298-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | ADIMABIO LLC | 2023-02-23 | — | — | US | claimed |
| WO-2023287797-A2 | A METHOD OF TREATING CANCER OR A BLOOD DISORDER | EBRAHEM QUTEBA (US) | 2023-01-19 | — | — | WO | claimed |
| EP-3960182-A1 | COMPOSITIONS CONTAINING DECITABINE, 5-AZACYTIDINE AND TETRAHYDROURIDINE AND USES THEREOF | Epidestiny, Inc. (US) | 2022-03-02 | — | — | EP | claimed |
| US-20260076988-A1 | TIMED ALTERNATE ADMINISTRATION OF DECITABINE AND 5-AZACYTIDINE FOR CANCER TREATMENT | CLEVELAND CLINIC FOUND (US) | 2026-03-19 | — | — | US | disclosed |
| CN-121571203-A | Cerium-based polyoxometallate supported metal organic framework composite material, preparation method thereof and application thereof in detecting antioxidant content | 河南大学 | 2026-02-27 | — | — | CN | disclosed |
| EP-4462543-B1 | AN ELECTROLYTE ADDITIVE AND A PREPARATION METHOD THEREFOR, AN ELECTROLYTE AND A LITHIUM ION BATTERY | JIANGSU ZENERGY BATTERY TECH GROUP CO LTD (CN) | 2026-01-21 | — | — | EP | disclosed |
| EP-3976054-B1 | TIMED ADMINISTRATION OF DECITABINE AND 5-AZACYTIDINE FOR CANCER TREATMENT | CLEVELAND CLINIC FOUND (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12486292-B2 | Prodrug platform useful to deliver amines, amides and phenols | Changchun Changcheng Pharmaceutical Technology Co., LTD (CN) | 2025-12-02 | — | — | US | disclosed |
| US-20140186335-A1 | Certain Compounds, Compositions and Methods | EISAI INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8268800-B2 | Certain compounds, compositions and methods | EISAI INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2447272-A1 | 2'-Fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors | Eisai Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-2207786-B1 | 2'-FLUORO-2'-DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS | EISAI INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20090137521-A1 | Certain Compounds, Compositions and Methods | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| WO-2009052287-A1 | 2 ' -FLU0R0-2 ' -DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS | EISAL CORPORATION OF NORTH AMERICA (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140186335-A1 | Certain Compounds, Compositions and Methods | DUT, TYMP, DPYD | CDA 134/4885MAPT 1627/4885SLC28A1 1165/4885 |
| US-20090137521-A1 | Certain Compounds, Compositions and Methods | DUT, TYMP, DPYD | CDA 134/4885MAPT 1627/4885SLC28A1 1165/4885 |
| US-20260076988-A1 | TIMED ALTERNATE ADMINISTRATION OF DECITABINE AND 5-AZACYTIDINE FOR CANCER TREATMENT | DCTD, ADA, DUT | CDA 4/4885MAPT 4571/4885SLC28A1 776/4885 |
| US-12486292-B2 | Prodrug platform useful to deliver amines, amides and phenols | GOT1, PAM, GLS2 | CDA 78/4885MAPT 376/4885SLC28A1 227/4885 |
| US-20230055298-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | TYMP, HBZ, HBB | CDA 4/4885MAPT 3834/4885SLC28A1 171/4885 |
| US-20230142647-A1 | METHOD OF TREATING CANCER OR A BLOOD DISORDER | XPO1, NPM1, XPOT | CDA 152/4885MAPT 2821/4885SLC28A1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.